Rushi Patel has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of Tacrolimus and Voclosporin as Induction Therapy in Lupus Nephritis: A Focused Systematic Review and Meta-Analysis of Randomized Evidence

    by Urvi Zala, Rushi Patel, Jacob Thompson, Anil Regmi

    Background: Lupus nephritis (LN) remains a major cause of morbidity among patients with systemic lupus erythematosus, and treatment resistance continues to pose clinical challenges. Calcineurin inhibitors (CNIs), including tacrolimus (TAC) and voclosporin (VCS), are used in induction regimens, but randomized evidence for the two agents arises from clinically different trial designs. This systematic review and meta-analysis separately quantifies randomized evidence for TAC-based and VCS-based induction regimens. Methods: Following PRISMA guidance, the literature search was updated to September 2026. Eligible studies were randomized controlled trials enrolling adults with biopsy-proven active class III, IV, or V LN and were required to report complete and/or partial renal-response data in a form permitting extraction or calculation of an effect estimate. Study inclusion was not based on whether the treatment effect was favorable or statistically significant. Complete renal response was the prespecified primary outcome for quantitative synthesis. Separate random-effects meta-analyses were performed for TAC-based and VCS-based regimens. Because the two evidence sets did not share a sufficiently comparable common comparator, no formal TAC-versus-VCS Bucher comparison was retained. Results: Five randomized controlled trials were included in the quantitative synthesis: three TAC trials and two VCS trials. TAC-based regimens increased complete renal response relative to their respective comparators (RR, 1.36; 95% CI, 1.00–1.86), although heterogeneity was substantial (I2 = 73%) and sensitivity analyses showed that the pooled result was influenced by the multitarget TAC + MMF trial. VCS added to MMF and low-dose glucocorticoids increased complete renal response versus the placebo with the same background therapy (RR, 1.78; 95% CI, 1.35–2.34; I2 = 0%). Safety outcomes were summarized descriptively because definitions and reporting differed across trials. Conclusions: TAC-based and VCS-based induction regimens each showed benefits within their respective randomized trial settings. Differences in background therapy, comparators, study populations, and outcome definitions preclude a reliable indirect efficacy comparison between TAC and VCS. Head-to-head randomized trials using standardized background therapy and outcomes are needed.

  • Open Access

    Use of Tacrolimus and Voclosporin as Induction Therapy in Lupus Nephritis: A Focused Systematic Review and Meta-Analysis of Randomized Evidence

    by Urvi Zala, Rushi Patel, Jacob Thompson, Anil Regmi

    Background: Lupus nephritis (LN) remains a major cause of morbidity among patients with systemic lupus erythematosus, and treatment resistance continues to pose clinical challenges. Calcineurin inhibitors (CNIs), including tacrolimus (TAC) and voclosporin (VCS), have emerged as adjuncts to standard induction therapy. This systematic review and meta-analysis identified and quantified the randomized evidence for TAC and for VCS as induction therapy in LN, summarizing the pooled effect of each agent against its trial comparators, with an exploratory adjusted indirect comparison provided for hypothesis generation. Methods: Following PRISMA guidelines, a comprehensive literature search was conducted through June 2025. Eligible studies were randomized controlled trials enrolling adults with biopsy-proven active class III, IV, or V LN and reporting complete or partial renal response after TAC- or VCS-based therapy. Pooled risk ratios (RRs) were calculated using a random-effects model, and an indirect Bucher comparison was performed. Results: Five multinational randomized controlled trials, including 1,433 participants, were analyzed. TAC significantly improved renal response compared with conventional induction therapy (RR, 1.36; 95% CI, 1.00–1.86; p = 0.048), with substantial heterogeneity (I² = 73%). VCS also significantly improved renal response (RR, 1.78; 95% CI, 1.35–2.34; p < 0.0001), with low heterogeneity (I² = 0%). Indirect comparison showed no statistically significant difference between TAC and VCS (RR, 0.79; 95% CI, 0.58–1.09; p = 0.08). Conclusion: Both TAC-based and VCS-based induction increased renal response relative to their respective comparators. A valid formal head-to-head comparison is not currently possible because the two evidence sets do not share a common comparator, and the exploratory indirect comparison showed no significant difference between agents. Choice between these agents should therefore rest on safety, tolerability, cost, and patient context rather than on a demonstrated efficacy advantage. Dedicated network meta-analyses address the broader treatment network in more formal terms.

  • Open Access

    Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study

    by Rushi Patel, Jacob Thompson, Namra Patel, Abhi C. Lohana, Fnu Versha, Subhash Chander, Viral Patel, Juan Iribarren

    Background/Objectives: Fixed-dose triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) at high risk of exacerbations; however, direct comparative effectiveness data between available triple therapy regimens remain limited. We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR). Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults with a spirometrically confirmed diagnosis of COPD who received fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) between July 2020 and August 2024 were included in the analysis. A 365-day landmark period was applied to establish maintenance therapy, with outcome follow-up beginning 1 year after treatment initiation. Patients were followed for outcomes through August 2025, the date of database analysis. After 1:1 propensity score matching, treatment groups were compared for COPD exacerbations, acute respiratory failure (ARF), hospitalization, and all-cause mortality using RR and Cox proportional hazards analyses. Results: In matched cohorts, FF/VI/UMEC was associated with a significantly higher risk of COPD exacerbations (5.6% vs. 3.9%; RR 1.44; 95% CI 1.30–1.59; p < 0.001) and ARF (2.5% vs. 1.9%; RR 1.28; 95% CI 1.11–1.46; p < 0.001) compared with BUD/GLY/FOR. Time-to-event analyses demonstrated lower event-free probability for exacerbations (HR 1.35; (95% CI 1.21–1.50) and ARF (HR 1.15; (95% CI 1.00–1.32))). All-cause mortality was numerically higher in the FF/VI/UMEC cohort (5.2% vs. 4.7%; RR 1.09; 95% CI 1.00–1.19; p = 0.050); however, time-to-event analysis did not demonstrate a statistically significant difference. Hospitalization rates were similar between groups. Conclusions: In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies.

  • Open Access

    Ketamine-Based ICU Sedation and Patient-Centered Outcomes: A Systematic Review and Meta-analysis of Mechanical Ventilation Duration, ICU Length of Stay, and Delirium

    by Rushi Patel, Jacob Thompson, Belal Elsayed, Mohamed Taher Alasfari, Viral Patel, Juan Irribarren

    Ketamine has been shown to possess unique pharmacologic properties that make it an appealing adjunctive sedative for critically ill patients; however, its overall impact on key intensive care unit (ICU) outcomes remains uncertain. As such, this systematic review and meta-analysis was conducted to evaluate whether intravenous ketamine-based sedation improves mechanical ventilation duration (MVD), ICU length of stay (LOS), and delirium incidence in ICU patients compared with standard analgosedation. Following PRISMA guidelines, a comprehensive literature search was conducted across online databases through June 2025. Eligible studies included randomized or prospective controlled adult ICU trials comparing continuous intravenous ketamine or esketamine infusions with standard sedation regimens. Pooled mean differences (MDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Six studies comprising 903 ICU patients met inclusion criteria. MVD was reported in all six studies; ICU LOS was reported in five studies and delirium was reported in two studies. Ketamine-based sedation was associated with a significant reduction in ICU LOS and a significant decrease in delirium incidence (MD: -0.86; 95% CI: -1.51, -0.22 and OR: 0.55; 95% CI: 0.43-0.72, respectively). Although MVD trended shorter in the ketamine group, this difference did not reach statistical significance (MD: -0.30; 95% CI: -1.53, 0.92). These results support consideration of ketamine as an adjunct in multimodal ICU sedation strategies; however, the effect on ventilation duration remains uncertain. While this study’s findings offer valuable comprehensive evaluations, further large-scale trials are needed to optimize dosing and confirm long-term benefits.

  • Open Access

    An Unusual Presentation of Juvenile Polymyositis in an Adolescent Girl

    by Rushi Patel, Urvi Zala, Joy Chaudhari, Viraj Panchal, Abhi Shah

    Juvenile idiopathic inflammatory myopathies (JIIMs) are a group of diverse, systemic autoimmune diseases that manifest in childhood and are characterized by weakness and chronic inflammation of skeletal muscles. One of the relatively rare variants of JIIMs is juvenile polymyositis (JPM). JPM patients present with proximal and distal muscle weakness, gait instability with falls, muscle pain and tenderness, and high levels of creatine kinase (CK) during adolescence. There are currently few people being diagnosed with JPM, which raises the question of whether or not it is a distinct disease. We discuss the case of a 13-year-old girl who presented to the hospital with generalized body swelling and difficulty swallowing solid food. She also had drooling of saliva during the presentation and a history of difficulty climbing up and down the stairs for three months. Her extensive laboratory workup showed a positive antinuclear antibody (ANA) test and increased muscle enzyme. A muscle biopsy was ordered, and she was diagnosed with JPM. Such a unique presentation has rarely been reported in the pediatric literature. This case report outlines an unusual JPM presentation that could help clinicians identify the condition and start treatment as soon as possible to minimize complications.